Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Deciphering RTK-RAS and MAPK Pathway Dependencies in Gemcitabine-Treated Pancreatic Ductal Adenocarcinoma Through Conversational Artificial Intelligence.

International journal of molecular sciences - 26 Mar 2026

Diaz Fernando C, Waldrup Brigette, Carranza Francisco G, Manjarrez Sophia, Velazquez-Villarreal Enrique

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy marked by substantial molecular heterogeneity and variable response to gemcitabine-based therapy. While KRAS mutations are nearly universal, the broader RTK-RAS and MAPK signaling architecture and its relationship to treatment response remain incompletely defined. We conducted an integrative clinical-genomic analysis of 184 PDAC tumors...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Artificial Intelligence

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Pancreatic Ductal

Share to Deoxycytidine

Share to Gemcitabine

Share to MAP Kinase Signaling System

Share to Pancreatic Neoplasms

Share to ras Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 41977200
DOI: 10.3390/ijms27073011
PMCID: PMC13072942

Genes

KRAS
ERBB2
FLNB
RET
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Deciphering RTK-RAS and MAPK Pathway Dependencies in Gemcitabine-Treated Pancreatic Ductal Adenocarcinoma Through Conversational Artificial Intelligence.PMID 41977200Read ↗

Conversational Artificial Intelligence Agents-Enabled Dissection of RTK-RAS and MAPK Pathway Dependencies in Gemcitabine-Treated Pancreatic Ductal Adenocarcinoma (PDAC)Semantic proximity Read ↗

Artificial Intelligence-Driven Identification of Age- and Treatment-Specific TP53 and PI3K Alterations in Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Conversational Artificial Intelligence-Enabled Precision Oncology Reveals Context-Specific TGFβ and JAK/STAT Alterations in Pancreatic CancerSemantic proximity Read ↗

Conversational Artificial Intelligence-Based Integration of Clinical and Genomic Data Identifies MAPK Alterations in Colorectal CancerSemantic proximity Read ↗

Artificial Intelligence-Driven Precision Oncology Uncovers Prognostic Significance of RTK-RAS Alterations in FOLFOX-Treated Early-Onset Colorectal CancerSemantic proximity Read ↗

From classical approaches to artificial intelligence, old and new tools for PDAC risk stratification and prediction.Semantic proximity Read ↗

Artificial intelligence for precision oncology: AI-HOPE-MAPK uncovers clinically actionable MAPK alterations in colorectal cancerSemantic proximity Read ↗

From Mutation to Prognosis: AI-HOPE-PI3K Enables Artificial Intelligence-Agent Driven Integration of PI3K Pathway Data in Colorectal Cancer Precision MedicineSemantic proximity Read ↗

Molecular Subtyping and Genomic Profiling Expand Precision Medicine in KRAS Wild‐Type Pancreatic CancerSemantic proximity Read ↗

Artificial Intelligence-Guided Molecular Determinants of PI3K Pathway Alterations in Early-Onset Colorectal Cancer Among High-Risk Groups Receiving FOLFOXSemantic proximity Read ↗

A Conversational Artificial Intelligence Framework for Comparative Pathway-Level Profiling of Sézary Syndrome and Primary Cutaneous CD8 <sup>+</sup> Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma (PCAECTCL)Semantic proximity Read ↗

A window trial in metastatic pancreatic ductal adenocarcinoma reveals resistance mechanisms to targeting the KRAS-MEK pathwaySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.